Chemed's dual-segment model—VITAS hospice and Roto-Rooter—provides a stable revenue base, but persistent gross margin compression from 36.6% in 2024Q4 to 30.4% in 2026Q2 and rising leverage (D/E up to 0.40) warrant caution. The company's aggressive buybacks ($...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth rebounded to 8.8% in 2026Q2, but gross margin fell 620 basis points from 36.6% in 2024Q4 to 30.4% in 2026Q2, indicating persistent cost pressures.
Chemed Corporation has a durable earnings profile, which is a key driver of its bullish investment case.
The company benefits from volatility-driven share repurchases, enhancing shareholder value.
Chemed Corporation demonstrates disciplined capital allocation, contributing to its strong financial performance.
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 28, 2026 | $6.06+8.2% vs $5.60 | $673M+1.2% vs $665M |
Q2 2026 Apr 23, 2026 | $5.65+6.6% vs $5.30 | $658M+1.2% vs $650M |
Q1 2026 Feb 25, 2026 | $6.42-8.5% vs $7.02 | $639M-3.0% vs $659M |
Q4 2025 Oct 28, 2025 | $5.27-2.2% vs $5.39 | $625M-5.2% vs $659M |
Corient Private Wealth LP raised its stake in shares of Chemed Corporation (NYSE: CHE) by 43.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,882 shares of the company's stock after purchasing an additional 1,488 shares during the
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Volatility and Risk Chemed has a beta of 0.51, suggesting
CINCINNATI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired the largest independent Roto-Rooter franchise, serving a population of approximately 11 million people, for $60.6 million.
Chemed Corporation (CHE) Presents at 2026 Jefferies Healthcare Services and Technology Conference Transcript
Benchmark CHE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Chemed Corporation (CHE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $502.90 | $6.68B | 27.30 | 4.06% | 10.48% | 25.28% | 0.44% | |
| $111.70 | $2.08B | 21.44 | 23.21% | 7.13% | 9.57% | — | |
| $169.63 | $9.89B | 29.05 | 18.72% | 6.9% | 16.51% | — | |
| $76.50 | $10.57B | 20.13 | 2.93% | 14.38% | 39.71% | — | |
| $31.79 | $504.58M | 9.78 | 3.28% | 10.67% | 17.07% | — | |
| $20.58 | $1.41B | 25.41 | 7.08% | 6.59% | 24.12% | — |
Chemed Corporation (CHE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Chemed Corporation (CHE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 28, 2026·SEC
May 19, 2026·SEC
Apr 23, 2026·SEC
Get notified when CHE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Chemed Corporation (CHE) stock FAQ — growth, dividends, profitability & financials explained
Chemed Corporation (CHE) reported $2.60B in revenue for fiscal year 2025. This represents a 762% increase from $301.2M in 1996.
Chemed Corporation (CHE) grew revenue by 4.1% over the past year. Growth has been modest.
Yes, Chemed Corporation (CHE) is profitable, generating $275.0M in net income for fiscal year 2025 (10.5% net margin).
Yes, Chemed Corporation (CHE) pays a dividend with a yield of 0.44%. This makes it attractive for income-focused investors.
Chemed Corporation (CHE) has a return on equity (ROE) of 25.3%. This is excellent, indicating efficient use of shareholder capital.
Chemed Corporation (CHE) generated $323.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
